Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-depe...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong Xiang (Author), Abigael G. Chan (Author), Ago Ahene (Author), David I. Bellovin (Author), Rong Deng (Author), Amy W. Hsu (Author), Ursula Jeffry (Author), Servando Palencia (Author), Janine Powers (Author), James Zanghi (Author), Helen Collins (Author)
Format: Book
Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available